特发性非肝硬化性门脉高压1例并文献复习

doi:10.3969/j.issn.1672-5069.2022.05.036

Abstract

Yang Jing, Cheng Yanli. Idiopathic non-cirrhotic portal hypertension: one case report and literature review[J]. Journal of Practical Hepatology, 2022, 25(5): 750-752.

[1]De Gottardi A, Rautou PE, Schouten J, et al. Porto-sinusoidal vascular disease: proposal and description of a novel entity. Lancet Gastroenterol Hepatol, 2019, 4(5):399-411.
[2]Lee H, Rehman AU, Fiel MI. Idiopathicnoncirrhotic portal hypertension: An appraisal. J Pathol Transl Med,2016,50(1):17-25.
[3]Guido M, Sarcognato S, Sacchi D. Pathology of idiopathic non-cirrhotic portal hypertension. Virchows Archiv,2018,473(1):23-31.
[4]Verhei J, Schouten JNL, Komuta M,et al. Histological features in western patients with idiopathic non-cirrhotic portal hypertension. Histopathology,2013,62(7):1083-1091.
[5]陈功海,王广川,张春清. 特发性非肝硬化门静脉高压症诊治进展. 中华消化病与影像杂志( 电子版),2021,11(3):132-138.
[6]Khanna R, Sarin SK. Idiopathic portal hypertension and extrahepatic portal venous obstruction. Hepatol Int, 2018, 12 (Suppl 1):148-167.
[7]Mallet VO, Varthaman A, Lasne D, et al. Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients. AIDS,2009,23(12):1511-1518.
[8]Schouten JNL, García-Pagán JC, Valla DC, et al. Idiopathic noncirrhotic portal hypertension. Hepatology, 2011,54:1071-1081.
[9]Koot BGP, Alders M, Verheij J, et al. A de novo mutation in KCNN3 associated with autosomal dominant idiopathic non-cirrhotic portal hypertension. J Hepatol, 2016,64(4):974-977.
[10] Eapen CE, Nightingale P, Hubscher SG, et al. Non-cirrhotic intrahepatic portal hypertension: associated Gut diseases and prognostic factors. Dig Dis Sci,2011,56(1):227-235.
[11] Vispo E, Moreno A, Maida I, et al. Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. AIDS,2010,24(8):1171-1176.
[12] Cazals-Hatem D, Hillaire S, Rudler M, et al. Obliterative portal venopathy: portal hypertension is not always present at diagnosis. J Hepatol,2011,54:455-461.
[13] Seinen ML,van Asseldonk DP,de Boer NK,et al. Nodular regenerative hyperplasia of the liver in patients with IBD treated with allopurinol-thiopurine combination therapy. Inflamm Bowel Dis,2017,23( 3): 448-452.
[14] Schouten JN,Verheij J, Seijo S. Idiopathic non-cirrhotic portal hypertension: a review. Orphanet J Rare Diss,2015,10: 67.
[15] Sarin SK,Kumar A. Noncirrhotic portal hypertension. Clin Liver Dis,2006,10(3): 627-651.
[16] Sato Y, Nakanuma Y. Role of endothelial-mesenchymal transition inidiopathic portal hypertension. Histol Histopathol,2013,28( 2):145-154.
[17] Khanna R,Sarin SK. Non-cirrhotic portal hypertension-diagnosis and management. J Hepatol,2014,60(2): 421-441.
[18] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol, 2016,64(1): 179-202.
[19] Guido M, Alves VAF, Balabaud C, et al. International Liver Pathology Study Group. Histology of portal vascular changes associated with idiopathic non-cirrhotic portal hypertension: nomenclature and definition. Histopathology,2019,74( 2): 219-226.
[20] 何福亮,马琳,李悦榕,等. 非肝硬化性门脉高压的临床诊断.实用肝脏病杂志, 2022,25(1):1-4.
[21] Plessier A, Rautou PE, Valla DC. Management of hepatic vascular diseases. J Hepatol, 2012, 56(Suppl. 1): S25-38.
[22] Elkrief L, Rautou PE. Idiopathic non-cirrhotic portal hypertension: the tip of the obliterative portal venopathies iceberg. Liver Int, 2016,36(3):325-327.

Idiopathic non-cirrhotic portal hypertension: one case report and literature review

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Luo Nan, Li Rongkuan. Spontaneous bacterial peritonitis in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(5): 616-619.
[2]	Mi Meng,Lu Bingjiu,Wang Xueliang, et al.. Analysis of blood lipid in patients with metabolism-related fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(5): 653-656.
[3]	Luo Suyan, Li Tingting, Wang Yaqi,et al.. Diagnostic performance of peripheral blood Treg/Th17 cells and their related cytokines in predicting significant liver fibrosis in patients with primary biliary cholangitis [J]. Journal of Practical Hepatology, 2022, 25(5): 673-676.
[4]	Gong Hao, Huang Li, Zhang Qinghong, et al.. Diagnostic efficacy of urine microalbumin, β2-microglobulin and N-acetyl-beta-glucosaminidase levels for renal injury in patients with decompensated liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(5): 681-684.
[5]	Huang Juan, Zhang Jichen. MRI LAVA scanning for collateral circulation in patients with Budd-Chiari syndrome [J]. Journal of Practical Hepatology, 2022, 25(5): 689-692.
[6]	Shi Ying, Bai Genji,Sun Yang. Diagnostic performance of multimodal MRI in differentiating dysplastic nodules and small hepatocellular carcinoma in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(5): 722-725.
[7]	Chronic Disease Management Branch, China Pharmaceutical Biotechnology Association. Expert consensus on the management of diabetes mellitus in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(5): 761-S1.
[8]	CheDepartment of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200092, Chinan Mengqi, Fan Jiangao. Brief introduction of a clinical practice guideline for the diagnosis and management of patients with nonalcoholic fatty liver diseases in USA [J]. Journal of Practical Hepatology, 2022, 25(5): 762-S16.
[9]	Mo Jinying, Yu Xi, Yu Xueping, et al. Diagnostic performance of FibroTouch scan in identifying liver fibrosis in hepatitis B virus carriers [J]. Journal of Practical Hepatology, 2022, 25(4): 480-483.
[10]	Luo Zhenzhen, Tian Haiying, Ge Jianhua, et al. Clinical evaluation of liver fibrosis by serum N-oligosaccharide and bile acid levels and liver stiffness measurement combination in patients with chronic hepatitis C [J]. Journal of Practical Hepatology, 2022, 25(4): 504-507.
[11]	Fu Lihong, Gao Yueqiu, Wang XiaoLin, et al. Liver pathological features of patients with drug-induced liver injury: An analysis of 38 cases [J]. Journal of Practical Hepatology, 2022, 25(4): 512-516.
[12]	Tang Lei, Peng Lei, Ye Jun, et al. Multivariate analysis of liver fibrosis progress in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2022, 25(4): 538-541.
[13]	Li Fang, Wang Yansen, Weng Luxin. Diagnostic performance of liver parenchymal texture feature quantification by high-frequency ultrasonography and serum AFP-L3 levels in the evaluation of liver function classification in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(4): 542-545.
[14]	Wang Baofeng, Ma Yangao, Li Yi, et al. Diagnostic efficacy of GD-EOB-DTPA enhanced MRI in differentiation of primary liver cancer from nodular regenerative hyperplasia of liver in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(4): 554-557.
[15]	Wang Jing, Zhang Jie, Zhao Jing. Differentiation of hepatic hemangioma from hepatocellular carcinoma by contrast ultrasonography and virtual touch tissue quantification: An analysis of 93 cases [J]. Journal of Practical Hepatology, 2022, 25(4): 575-578.